It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardian

Recent lecanemab trials are reason for hope, although health services may struggle to deliver treatments, says dementia researcher Jonathan Schott

Photograph: Tek/Getty/Science Photo Library RF View image in fullscreen Photograph: Tek/Getty/Science Photo Library RF Opinion Alzheimer's This article is more than 3 years old It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough This article is more than 3 years old Jonathan Schott Recent lecanemab trials are reason for hope. But the NHS and other health services may struggle to deliver these new treatments NHS ‘nowhere near ready’ to deliver new Alzheimer’s drug, doctors say Wed 30 Nov 2022 04.48 EST Last modified on Wed 30 Nov 2022 12.43 EST Share I t is 20 yea

saved by

• David Song

related reading

• Nintil - The failure of monoclonal antibody therapy for Alzheimer's Disease, implications for the Amyloid Cascade Hypothesisnintil.com
• AI for Alzheimer’sopenaifoundation.org
• Contrary Research on X: "The Virtual Cell Revolution" / Xx.com
• 'Breakthrough' blood test can find dementia risk before symptoms startnypost.com
• FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease | FDAfda.gov
• Eye test can detect early Alzheimer'stherecord.com
• Alzheimer’s drug trial explores gut-brain linknature.com
• Dario Amodei — Machines of Loving Gracedarioamodei.com
• “Real world” eligibility for aducanumab: A Podcast with Tim Anderson and Marco Canevelligeripal.org
• The fall of Cassava Sciences’s Alzheimer’s drug, simufilamhealthcare-brew.com
• Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io